New hope for advanced cervical cancer? eribulin under study
NCT ID NCT01676818
First seen Nov 06, 2025 · Last updated Jun 10, 2026 · Updated 23 times
Summary
This study tested the chemotherapy drug eribulin in 32 people with advanced or recurrent cervical cancer that had spread. The goal was to see how long the drug could keep the cancer from growing and to check for side effects. Participants had already tried up to one prior chemotherapy regimen for their advanced disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.